2024 has seen a surge in research exploring ivermectin’s potential beyond its conventional use as an antiparasitic drug, particularly in the field of oncology. Multiple studies have highlighted ivermectin’s ability to inhibit cancer cell growth, with some preliminary data suggesting benefits in treating mRNA vaccine-induced ‘turbo cancers’.
Dr. William Makis, among others, has proposed protocols incorporating ivermectin for such cancers, advocating for its use in combination with other therapies to enhance outcomes. These studies have sparked a debate on ivermectin’s repurposing, with some oncologists cautiously optimistic about its role in cancer treatment.
However, the scientific community remains divided, emphasizing the need for more comprehensive clinical trials to validate these findings. Critics highlight the risk of over-optimism, stressing the importance of rigorous scientific scrutiny before ivermectin can be recommended for cancer treatment.
This year could mark a significant turning point if further research corroborates these initial findings, potentially expanding ivermectin’s therapeutic scope.
